Lantern Pharma
LTRN
31 hedge funds and large institutions have $4.9M invested in Lantern Pharma in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 11 closing their positions.
773% more call options, than puts
Call options by funds: $192K | Put options by funds: $22K
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
0.45% more ownership
Funds ownership: 11.95% → 12.4% (+0.45%)
18% less capital invested
Capital invested by funds: $6.01M → $4.9M (-$1.1M)
21% less funds holding
Funds holding: 39 → 31 (-8)
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
CM Management
Gulf Breeze,
Florida
|
+$432K |
| 2 |
PWM
Perigon Wealth Management
San Francisco,
California
|
+$119K |
| 3 |
WIM
Westside Investment Management
Santa Monica,
California
|
+$78.9K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$78.8K |
| 5 |
Renaissance Technologies
New York
|
+$9.06K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$156K |
| 2 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$81.5K |
| 3 |
MWM
Meridian Wealth Management
Lexington,
Kentucky
|
-$69.8K |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
-$60.2K |
| 5 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$50.9K |
LTRN Hedge Fund Activity: Q3 2024 in Review
31 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q3 2024, worth a combined $4.9M — down 18% from $6.01M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of LTRN and 3 opened new positions — a net loss of 8 holders — while 8 trimmed existing stakes and 10 added.
The largest buyer was CM Management, adding an estimated $432K. The largest seller was Susquehanna International Group, cutting an estimated $156K.
- 31 institutional investors held Lantern Pharma (LTRN) as of Q3 2024, down from 39 in Q2 2024.
- Funds reported $4.9M of Lantern Pharma stock for Q3 2024, down 18% quarter-over-quarter.
- 3 funds opened new Lantern Pharma positions in Q3 2024 and 11 closed out, a net change of -8 holders.
- The largest Lantern Pharma buyer in Q3 2024 was CM Management, an estimated $432K added.
- The largest Lantern Pharma seller in Q3 2024 was Susquehanna International Group, an estimated $156K sold.
Based on aggregated 13F filings for Q3 2024.